MAP2K7 and glioblastoma: However, the majority of glioblastoma patients fail to respond to treatments with either PI3K/Akt or MEK/ERK signaling inhibitors [7], suggesting that a single suppression of one signaling pathway may be insufficient for effectively treating this tumor.